Financial Performance - The Company reported a revenue of RMB 299,718,000 for the three months ended March 31, 2023, representing a 38.9% increase compared to RMB 215,698,000 in the same period of 2022[9]. - Gross profit for the reporting period was RMB 140,803,000, up 43.4% from RMB 97,543,000 year-over-year[9]. - Profit before taxation increased to RMB 22,309,000, a 50.1% rise from RMB 14,842,000 in the previous year[10]. - The net profit attributable to the owners of the Company was RMB 16,264,000, compared to RMB 10,541,000 in the same period last year, marking a 54.5% increase[10]. - Basic and diluted earnings per share for the period were RMB 0.97 cents, up from RMB 0.63 cents in the prior year, reflecting a 54% increase[10]. - The Company reported total comprehensive income for the period of RMB 19,198,000, which is a 67.1% increase from RMB 11,508,000 in the previous year[10]. Revenue Breakdown - Revenue from manufacturing and selling medicines was RMB 216,653,000, up 43.7% from RMB 150,703,000 in the previous year[21]. - Revenue from sales and distribution of medicines and healthcare products increased to RMB 83,065,000, a rise of 28.0% from RMB 64,995,000 in 2022[21]. - Other revenue totaled RMB 3,167,000, which is a 40.4% increase from RMB 2,256,000 in the prior year[24]. - The Group's revenue primarily comes from the sale of medicines across various therapeutic areas, including oncology and cardiovascular systems[44][46]. Expenses - Selling and distribution expenses rose to RMB 87,457,000, an increase of 63.6% from RMB 53,440,000 in the previous year[9]. - Administrative expenses remained relatively stable at RMB 22,959,000, compared to RMB 22,364,000 in the same period last year[10]. - Staff costs increased to RMB 38,278,000, reflecting a rise of 2.3% from RMB 37,401,000 in the same period last year[27]. - Research and development costs were RMB 7,319,000, which is an increase of 6.1% compared to RMB 6,897,000 in the previous year[30]. - Other operating expenses amounted to approximately RMB 9,955,000, representing an increase of approximately 20.50% from RMB 8,261,000 for the corresponding period last year[65]. Taxation - Current tax provision for the period was RMB 3,413,000, compared to RMB 3,219,000 in the same period of 2022[34]. - The effective tax rate for the qualified high technology enterprises was 15%, while other subsidiaries were subject to a 25% rate[35]. Equity and Shareholding - The total equity of the Company as of March 31, 2023, was RMB 1,024,502,000, reflecting growth from RMB 955,908,000 at the same time last year[11]. - As of March 31, 2023, Neptunus Bio-engineering holds approximately 73.51% of the entire issued share capital of the Company, with 70.38% directly held and 3.13% indirectly held through Shenzhen Neptunus Oriental Investment Company Limited[81]. - Neptunus Bio-engineering holds 1,181,000,000 domestic shares, representing 94.33% of all domestic shares and 70.38% of the company's issued share capital[92]. Corporate Governance - The Company has established an Audit Committee to review financial statements and provide suggestions to the Board[108]. - The Audit Committee has reviewed the unaudited consolidated results for the Reporting Period[109]. - The Company has complied with the Corporate Governance Code during the Reporting Period[116]. - The roles of the Chairman and General Manager are separate, with Mr. Zhang Feng serving as the current Chairman[110]. - The Company is in the process of identifying a suitable candidate for the General Manager position following the resignation of Mr. Zhou Hang[115]. - The Company is committed to maintaining compliance with GEM Listing Rules[116]. Research and Development - The Group's research and development efforts focus on both independent projects and collaborations with external institutions, emphasizing innovation in generic medicines and new drug development[49][50]. - The Group owns a total of 35 patents for inventions, with four products having passed the consistency evaluation, including Sodium Bicarbonate Tablets and Metformin Hydrochloride Tablets[49][50]. - The Group has received approvals for new products, including Doxofylline Injection and Concentrated Sodium Potassium Magnesium Calcium Injection, enhancing its product portfolio[49][50]. Dividends and Share Options - No dividends were recommended for the reporting period, consistent with the previous year[37][40]. - The Company and its subsidiaries have not adopted any share option scheme or granted any options, convertible securities, or warrants as of March 31, 2023[83]. - During the reporting period, no Directors or supervisors were granted any share options, warrants, or convertible bonds[84].
海王英特龙(08329) - 2023 Q1 - 季度财报